NOS3 and stroke disorder: Sub-group analysis revealed that in a large eNOS trial, transdermal glyceryl trinitrate administered within 6 hours of stroke onset significantly improves neurological function, decreases deaths, lowers blood pressure and improves cognitive outcome at 90 days compared to non-treated control group [75].